Xianghong Jasmine Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xianghong Jasmine Zhou has a total of 187 co-authors. Here are the top co-authors by number of shared publications:
- Wenyuan Li
Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA
15 shared publications - Shuo Li
Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California at Los Angeles
11 shared publications - Edward Brian Garon
Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, USA
9 shared publications Yonggang Zhou
Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California at Los Angeles
9 shared publications- Vatche G. Agopian
Division of Liver and Pancreas Transplantation, Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
8 shared publications - Wing Hung Wong
Department of Statistics, Stanford University
8 shared publications
Latest Publications
- Open Access
- 4 October 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
A CCL21 gene-modified dendritic cell vaccine combined with pembrolizumab in advanced non-small cell lung cancer: a phase I trial
Immune checkpoint inhibitors (ICIs) have transformed treatment for non-small cell lung cancer (NSCLC), but resistance to these therapies is common. We report here results from a phase I trial combining intratumoral injection of a CCL21-expressing dendritic cell (CCL21-DC) vaccine with pembrolizumab in patients with advanced non-small cell lung cancer (ClinicalTrials.gov identifier: NCT03546361). The primary objectives were to determine the maximum administered dose (MAD) in the dose escalation phase and the objective response rate (ORR) in the dose expansion. Eleven patients were enrolled in the dose escalation cohort, and 12 patients were treated in the dose expansion cohort at the MAD of 3 ×10 7 cells/injection. The trial did not meet its primary endpoint for ORR as no objective responses were observed, though 36.8% of patients achieved a best response of stable disease. The combination therapy was well tolerated. Post-hoc analyses of longitudinal biopsies revealed that the therapy increased tumor infiltration by CD4+ T cells and novel T cell clones. Disease stability was associated with increased T cell receptor diversity and greater expansion of novel clones following therapy. However, many novel clones failed to persist over time, and immunosuppressive myeloid signaling signatures were identified across time points. Our findings overall demonstrated that CCL21-DC vaccination combined with pembrolizumab can promote T cell infiltration, but this did not translate into meaningful clinical efficacy, potentially due to limited tumor specificity of the T cell response and an inability to fully reprogram the tumor microenvironment.
- 4 October 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessA CCL21 gene-modified dendritic cell vaccine combined with pembrolizumab in advanced non-small cell lung cancer: a phase I trial
Immune checkpoint inhibitors (ICIs) have transformed treatment for non-small cell lung cancer (NSCLC), but resistance to these therapies is common. We report here results from a phase I trial combining intratumoral injection of a CCL21-expressing dendritic cell (CCL21-DC) vaccine with pembrolizumab in patients with advanced non-small cell lung cancer (ClinicalTrials.gov identifier: NCT03546361). The primary objectives were to determine the maximum administered dose (MAD) in the dose escalation phase and the objective response rate (ORR) in the dose expansion. Eleven patients were enrolled in the dose escalation cohort, and 12 patients were treated in the dose expansion cohort at the MAD of 3 ×10 7 cells/injection. The trial did not meet its primary endpoint for ORR as no objective responses were observed, though 36.8% of patients achieved a best response of stable disease. The combination therapy was well tolerated. Post-hoc analyses of longitudinal biopsies revealed that the therapy increased tumor infiltration by CD4+ T cells and novel T cell clones. Disease stability was associated with increased T cell receptor diversity and greater expansion of novel clones following therapy. However, many novel clones failed to persist over time, and immunosuppressive myeloid signaling signatures were identified across time points. Our findings overall demonstrated that CCL21-DC vaccination combined with pembrolizumab can promote T cell infiltration, but this did not translate into meaningful clinical efficacy, potentially due to limited tumor specificity of the T cell response and an inability to fully reprogram the tumor microenvironment.
- Open Access
- 19 June 2026
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 10 (7)
Methylation plus alpha-fetoprotein blood test for early detection of HCC in at-risk populations
Background: Semi-annual abdominal ultrasound plus alpha-fetoprotein (AFP) is recommended for HCC surveillance but has limited performance, particularly in patients with metabolic dysfunction–associated steatotic liver disease. We aimed to validate a blood-based test combining cell-free DNA methylation profiling with AFP to improve HCC detection in at-risk individuals. Methods: Between September 1, 2023, and April 30, 2025, 135 patients with HCC and 167 at risk for HCC were prospectively recruited at 2o medical centers; archived samples (46 HCC and 32 at-risk) were also included. A cell-free DNA methylation assay was performed to generate methylation scores, and AFP testing was conducted as part of standard of care. A pretrained model integrated methylation scores and AFP levels for HCC detection. Results: The combination of methylation and AFP tests achieved an AUC of 0.94 (95% CI, 0.92–0.96) for detecting HCC in at-risk individuals, significantly outperforming both methylation alone (AUC: 0.92, 95% CI, 0.89–0.95; p =0.001) and AFP alone (AUC: 0.83, 95% CI, 0.79–0.87; p p =0.002) and AFP alone (AUC: 0.81, 95% CI, 0.76–0.86; p p =0.025) for methylation alone and 52% (95% CI, 43%–62%; p <0.0001) for AFP alone. Sensitivity improvements were consistent across major demographic and etiologic subgroups. Conclusions: The combination of cell-free DNA methylation with AFP shows promising performance for early-stage HCC detection in this case-control validation study and warrants further validation.
- 19 June 2026
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 10 (7)
Open AccessMethylation plus alpha-fetoprotein blood test for early detection of HCC in at-risk populations
Background: Semi-annual abdominal ultrasound plus alpha-fetoprotein (AFP) is recommended for HCC surveillance but has limited performance, particularly in patients with metabolic dysfunction–associated steatotic liver disease. We aimed to validate a blood-based test combining cell-free DNA methylation profiling with AFP to improve HCC detection in at-risk individuals. Methods: Between September 1, 2023, and April 30, 2025, 135 patients with HCC and 167 at risk for HCC were prospectively recruited at 2o medical centers; archived samples (46 HCC and 32 at-risk) were also included. A cell-free DNA methylation assay was performed to generate methylation scores, and AFP testing was conducted as part of standard of care. A pretrained model integrated methylation scores and AFP levels for HCC detection. Results: The combination of methylation and AFP tests achieved an AUC of 0.94 (95% CI, 0.92–0.96) for detecting HCC in at-risk individuals, significantly outperforming both methylation alone (AUC: 0.92, 95% CI, 0.89–0.95; p =0.001) and AFP alone (AUC: 0.83, 95% CI, 0.79–0.87; p p =0.002) and AFP alone (AUC: 0.81, 95% CI, 0.76–0.86; p p =0.025) for methylation alone and 52% (95% CI, 43%–62%; p <0.0001) for AFP alone. Sensitivity improvements were consistent across major demographic and etiologic subgroups. Conclusions: The combination of cell-free DNA methylation with AFP shows promising performance for early-stage HCC detection in this case-control validation study and warrants further validation.
- Open Access
- 6 April 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (15)
Toward the simultaneous detection of multiple diseases with a highly cost-effective cell-free DNA methylome test
Plasma cell-free DNA (cfDNA), originating from multiple organs, holds significant potential for noninvasive diagnostics and prognostics. Current cfDNA methylation assays primarily focus on single clinical indications by targeting specific genomic loci. In contrast, comprehensive profiling of cfDNA methylome can enable simultaneous detection of multiple diseases by capturing organ-specific methylation signatures, thereby offering a holistic view of health, when disease etiology is unclear or when conventional biochemical diagnostics are unavailable. However, deep sequencing required for sensitive detection of methylation abnormalities remains prohibitively expensive, limiting widespread clinical use. To overcome this barrier, we developed MethylScan , a highly cost-effective approach for cfDNA methylome sequencing. We demonstrated its broad clinical utility in a cohort of 1,061 individuals across diverse applications, including multicancer detection in general population, liver cancer surveillance in high-risk individuals, liver disease classification, identification of organ abnormalities, and race prediction from cfDNA. In multicancer detection (liver, lung, ovarian, and stomach cancers), MethylScan achieved an area under the receiver operating characteristic curve (AUROC) of 0.938 (95% CI: 0.920 to 0.954), with a sensitivity of 63.3% (95% CI: 58.9 to 67.9%) at 98.0% specificity for all cancer stages. For early-stage cancers, the AUROC was 0.916 (95% CI: 0.890 to 0.940), with 55.3% sensitivity (95% CI: 49.1 to 62.1%) at the same specificity. In liver cancer surveillance, MethylScan achieved an AUROC of 0.927 (95% CI: 0.889 to 0.959), with 79.6% sensitivity (95% CI: 70.6 to 87.8%) at 90.4% specificity. The assay also demonstrated strong performance in additional diagnostic tasks, supporting its potential as a versatile platform for comprehensive cfDNA-based health monitoring.
- 6 April 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (15)
Open AccessToward the simultaneous detection of multiple diseases with a highly cost-effective cell-free DNA methylome test
Plasma cell-free DNA (cfDNA), originating from multiple organs, holds significant potential for noninvasive diagnostics and prognostics. Current cfDNA methylation assays primarily focus on single clinical indications by targeting specific genomic loci. In contrast, comprehensive profiling of cfDNA methylome can enable simultaneous detection of multiple diseases by capturing organ-specific methylation signatures, thereby offering a holistic view of health, when disease etiology is unclear or when conventional biochemical diagnostics are unavailable. However, deep sequencing required for sensitive detection of methylation abnormalities remains prohibitively expensive, limiting widespread clinical use. To overcome this barrier, we developed MethylScan , a highly cost-effective approach for cfDNA methylome sequencing. We demonstrated its broad clinical utility in a cohort of 1,061 individuals across diverse applications, including multicancer detection in general population, liver cancer surveillance in high-risk individuals, liver disease classification, identification of organ abnormalities, and race prediction from cfDNA. In multicancer detection (liver, lung, ovarian, and stomach cancers), MethylScan achieved an area under the receiver operating characteristic curve (AUROC) of 0.938 (95% CI: 0.920 to 0.954), with a sensitivity of 63.3% (95% CI: 58.9 to 67.9%) at 98.0% specificity for all cancer stages. For early-stage cancers, the AUROC was 0.916 (95% CI: 0.890 to 0.940), with 55.3% sensitivity (95% CI: 49.1 to 62.1%) at the same specificity. In liver cancer surveillance, MethylScan achieved an AUROC of 0.927 (95% CI: 0.889 to 0.959), with 79.6% sensitivity (95% CI: 70.6 to 87.8%) at 90.4% specificity. The assay also demonstrated strong performance in additional diagnostic tasks, supporting its potential as a versatile platform for comprehensive cfDNA-based health monitoring.
- Open Access
- 25 February 2026
- Published by Springer Nature in Genome Biology
- Vol. 27 (1)
Reducing demographic bias in biomedical machine learning for cancer detection using cfDNA methylation
Background: Machine learning models in biomedical research are often hindered by demographic imbalances in clinical datasets, leading to biased predictions that disadvantage minority populations. Existing bias-correction methods face limitations in handling the heterogeneity of biomedical data and the complexity of demographic influences. Results: We present DeBias , a computational framework for mitigating demographic biases in high-dimensional biomedical datasets. DeBias identifies and removes bias-associated subspaces from the feature space using control samples, enabling global correction of demographic distortions while preserving disease-specific signals. To evaluate its effectiveness, we apply DeBias to cell-free DNA methylation data for cancer detection. DeBias achieves a significant reduction in the number of features exhibiting demographic bias and outperforms existing methods in improving cancer detection performance for minority populations. Performance gains are validated in independent cohorts, highlighting the robustness of the approach. Conclusions: DeBias offers an effective and generalizable strategy for correcting demographic biases in biomedical machine learning. It represents a step toward more equitable machine learning models that can deliver reliable and unbiased predictions across diverse patient populations.
- 25 February 2026
- Published by Springer Nature in Genome Biology
- Vol. 27 (1)
Open AccessReducing demographic bias in biomedical machine learning for cancer detection using cfDNA methylation
Background: Machine learning models in biomedical research are often hindered by demographic imbalances in clinical datasets, leading to biased predictions that disadvantage minority populations. Existing bias-correction methods face limitations in handling the heterogeneity of biomedical data and the complexity of demographic influences. Results: We present DeBias , a computational framework for mitigating demographic biases in high-dimensional biomedical datasets. DeBias identifies and removes bias-associated subspaces from the feature space using control samples, enabling global correction of demographic distortions while preserving disease-specific signals. To evaluate its effectiveness, we apply DeBias to cell-free DNA methylation data for cancer detection. DeBias achieves a significant reduction in the number of features exhibiting demographic bias and outperforms existing methods in improving cancer detection performance for minority populations. Performance gains are validated in independent cohorts, highlighting the robustness of the approach. Conclusions: DeBias offers an effective and generalizable strategy for correcting demographic biases in biomedical machine learning. It represents a step toward more equitable machine learning models that can deliver reliable and unbiased predictions across diverse patient populations.
- Open Access
- 5 February 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 1388
Author Correction: Sensitive detection of tumor mutations from blood and its application to immunotherapy prognosis
- 5 February 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 1388
Open AccessAuthor Correction: Sensitive detection of tumor mutations from blood and its application to immunotherapy prognosis
- Open Access
- 22 May 2025
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 53 (10)
3D genome organization shapes DNA damage susceptibility to platinum-based drugs
Platinum (Pt) drugs are widely utilized in cancer chemotherapy. Although cytotoxic and resistance mechanisms of Pt drugs have been thoroughly explored, it remains elusive what factors affect the receptiveness of DNA to drug-induced damage in nuclei. Here, we demonstrate that nuclear locations of chromatin play a key role in Pt drug-induced DNA damage susceptibility in vivo. By integrating data from damage-seq experiments with 3D genome structure information, we show that nuclear locations of chromatin relative to specific nuclear bodies and compartments explain patterns of cisplatin DNA damage susceptibility. This aligns with observations of cisplatin enrichment in biomolecular condensates at certain nuclear bodies. Finally, 3D structure mapping of DNA damage reveals characteristic differences between nuclear distributions of oxaliplatin-induced DNA damage in drug resistant versus sensitive cells. DNA damage increases in gene-poor chromatin at the nuclear periphery, while it decreases in gene-rich regions located at nuclear speckles. This suggests a strategic redistribution of Pt drug-induced damage in nuclei during chemoresistance development.
- 22 May 2025
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 53 (10)
Open Access3D genome organization shapes DNA damage susceptibility to platinum-based drugs
Platinum (Pt) drugs are widely utilized in cancer chemotherapy. Although cytotoxic and resistance mechanisms of Pt drugs have been thoroughly explored, it remains elusive what factors affect the receptiveness of DNA to drug-induced damage in nuclei. Here, we demonstrate that nuclear locations of chromatin play a key role in Pt drug-induced DNA damage susceptibility in vivo. By integrating data from damage-seq experiments with 3D genome structure information, we show that nuclear locations of chromatin relative to specific nuclear bodies and compartments explain patterns of cisplatin DNA damage susceptibility. This aligns with observations of cisplatin enrichment in biomolecular condensates at certain nuclear bodies. Finally, 3D structure mapping of DNA damage reveals characteristic differences between nuclear distributions of oxaliplatin-induced DNA damage in drug resistant versus sensitive cells. DNA damage increases in gene-poor chromatin at the nuclear periphery, while it decreases in gene-rich regions located at nuclear speckles. This suggests a strategic redistribution of Pt drug-induced damage in nuclei during chemoresistance development.
- Open Access
- 1 May 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1
Author Correction: Cost-effective methylome sequencing of cell-free DNA for accurately detecting and locating cancer
- 1 May 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1
Open AccessAuthor Correction: Cost-effective methylome sequencing of cell-free DNA for accurately detecting and locating cancer
- Open Access
- 3 January 2024
- Published by Springer Nature in Nature Protocols
- Vol. 19 (4) , 1289
Author Correction: cfSNV: a software tool for the sensitive detection of somatic mutations from cell-free DNA
- 3 January 2024
- Published by Springer Nature in Nature Protocols
- Vol. 19 (4) , 1289
Open AccessAuthor Correction: cfSNV: a software tool for the sensitive detection of somatic mutations from cell-free DNA
- Open Access
- 14 August 2023
- Published by Springer Nature in Nature Structural & Molecular Biology
- Vol. 30 (8) , 1193-1206
Evaluating the role of the nuclear microenvironment in gene function by population-based modeling
The nuclear folding of chromosomes relative to nuclear bodies is an integral part of gene function. Here, we demonstrate that population-based modeling—from ensemble Hi-C data—provides a detailed description of the nuclear microenvironment of genes and its role in gene function. We define the microenvironment by the subnuclear positions of genomic regions with respect to nuclear bodies, local chromatin compaction, and preferences in chromatin compartmentalization. These structural descriptors are determined in single-cell models, thereby revealing the structural variability between cells. We demonstrate that the microenvironment of a genomic region is linked to its functional potential in gene transcription, replication, and chromatin compartmentalization. Some chromatin regions feature a strong preference for a single microenvironment, due to association with specific nuclear bodies in most cells. Other chromatin shows high structural variability, which is a strong indicator of functional heterogeneity. Moreover, we identify specialized nuclear microenvironments, which distinguish chromatin in different functional states and reveal a key role of nuclear speckles in chromosome organization. We demonstrate that our method produces highly predictive three-dimensional genome structures, which accurately reproduce data from a variety of orthogonal experiments, thus considerably expanding the range of Hi-C data analysis.
- 14 August 2023
- Published by Springer Nature in Nature Structural & Molecular Biology
- Vol. 30 (8) , 1193-1206
Open AccessEvaluating the role of the nuclear microenvironment in gene function by population-based modeling
The nuclear folding of chromosomes relative to nuclear bodies is an integral part of gene function. Here, we demonstrate that population-based modeling—from ensemble Hi-C data—provides a detailed description of the nuclear microenvironment of genes and its role in gene function. We define the microenvironment by the subnuclear positions of genomic regions with respect to nuclear bodies, local chromatin compaction, and preferences in chromatin compartmentalization. These structural descriptors are determined in single-cell models, thereby revealing the structural variability between cells. We demonstrate that the microenvironment of a genomic region is linked to its functional potential in gene transcription, replication, and chromatin compartmentalization. Some chromatin regions feature a strong preference for a single microenvironment, due to association with specific nuclear bodies in most cells. Other chromatin shows high structural variability, which is a strong indicator of functional heterogeneity. Moreover, we identify specialized nuclear microenvironments, which distinguish chromatin in different functional states and reveal a key role of nuclear speckles in chromosome organization. We demonstrate that our method produces highly predictive three-dimensional genome structures, which accurately reproduce data from a variety of orthogonal experiments, thus considerably expanding the range of Hi-C data analysis.
- Open Access
- 3 July 2023
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 120 (28)
Comprehensive tissue deconvolution of cell-free DNA by deep learning for disease diagnosis and monitoring
Plasma cell-free DNA (cfDNA) is a noninvasive biomarker for cell death of all organs. Deciphering the tissue origin of cfDNA can reveal abnormal cell death because of diseases, which has great clinical potential in disease detection and monitoring. Despite the great promise, the sensitive and accurate quantification of tissue-derived cfDNA remains challenging to existing methods due to the limited characterization of tissue methylation and the reliance on unsupervised methods. To fully exploit the clinical potential of tissue-derived cfDNA, here we present one of the largest comprehensive and high-resolution methylation atlas based on 521 noncancer tissue samples spanning 29 major types of human tissues. We systematically identified fragment-level tissue-specific methylation patterns and extensively validated them in orthogonal datasets. Based on the rich tissue methylation atlas, we develop the first supervised tissue deconvolution approach, a deep-learning-powered model, cfSort , for sensitive and accurate tissue deconvolution in cfDNA. On the benchmarking data, cfSort showed superior sensitivity and accuracy compared to the existing methods. We further demonstrated the clinical utilities of cfSort with two potential applications: aiding disease diagnosis and monitoring treatment side effects. The tissue-derived cfDNA fraction estimated from cfSort reflected the clinical outcomes of the patients. In summary, the tissue methylation atlas and cfSort enhanced the performance of tissue deconvolution in cfDNA, thus facilitating cfDNA-based disease detection and longitudinal treatment monitoring.
- 3 July 2023
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 120 (28)
Open AccessComprehensive tissue deconvolution of cell-free DNA by deep learning for disease diagnosis and monitoring
Plasma cell-free DNA (cfDNA) is a noninvasive biomarker for cell death of all organs. Deciphering the tissue origin of cfDNA can reveal abnormal cell death because of diseases, which has great clinical potential in disease detection and monitoring. Despite the great promise, the sensitive and accurate quantification of tissue-derived cfDNA remains challenging to existing methods due to the limited characterization of tissue methylation and the reliance on unsupervised methods. To fully exploit the clinical potential of tissue-derived cfDNA, here we present one of the largest comprehensive and high-resolution methylation atlas based on 521 noncancer tissue samples spanning 29 major types of human tissues. We systematically identified fragment-level tissue-specific methylation patterns and extensively validated them in orthogonal datasets. Based on the rich tissue methylation atlas, we develop the first supervised tissue deconvolution approach, a deep-learning-powered model, cfSort , for sensitive and accurate tissue deconvolution in cfDNA. On the benchmarking data, cfSort showed superior sensitivity and accuracy compared to the existing methods. We further demonstrated the clinical utilities of cfSort with two potential applications: aiding disease diagnosis and monitoring treatment side effects. The tissue-derived cfDNA fraction estimated from cfSort reflected the clinical outcomes of the patients. In summary, the tissue methylation atlas and cfSort enhanced the performance of tissue deconvolution in cfDNA, thus facilitating cfDNA-based disease detection and longitudinal treatment monitoring.